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Poster Session II S305Data were collected and analyzed retrospectively using KSGCT
database and survey sheets.
Results: Four hundred fifty patients (255 males and 195 females)
with a median age of 44-year-old (range 15-68) were included in
this study. All patients had underlying hematological malignancies
except 13 patients with aplastic anemia. Median serum creatinine
level before conditioning was 0.64 (0.32 - 1.33) mg/dl. After correct-
ing the Ccr data by actual body surface area in patients whose body
heights and body weights were available, corrected Ccr was 107 (34 -
372) ml/min/1.73m2. Patients with mildly reduced renal function (\
90 ml/min/1.73 m2) were further classified into group 1 (23 patients,
5.6%) and group 2 (97 patients, 23.7%), according to the corrected
Ccr of 30-59 and 60-89 ml/min/1.73 m2, respectively. Twenty-four
patients (19 patients within 100 days and 5 patients after 100 days)
developed severe renal failure which required hemodialysis after
HSCT. Hemodialysis was discontinued in 5 patients upon recovery
of renal function. Probability of requiring hemodialysis was 13% in
the group 1, which was higher than that in the group 2 (2.1%) and
that in the normal renal function group (6.6%), but the difference
was not statistically significant. The incidences of NRM within 30
days or 100 days after HSCT and grade II to IV acute graft-ver-
sus-host disease did not differ among these three groups.
Conclusion: Similarly to the results of HCT-CI analysis, mildly
reduced renal function before allogeneic HSCT did not affect the
outcome of HSCT.Table 1. Patient, Disease, and Transplantation Characteristics
Characteristic Evaluable-10
Age
Mean 57.5
Range 42-71
Male sex 2
Disease
AML 8
ALL 2
Time between diagnosis and SCT
Mean 446.4
Range 161-1683
Donor
MRD 4
MUD 6
Cohort 1A 6
Cohort 2A 3
Cohort 1B 1
Cycles of chemotherapy prior to SCT
Mean 4
Range 2-9
Bone marrow blasts at starting CPX
Mean 50
Range 8-83
Circulating blasts at starting CPX
Mean 33.4
Range 0-49
CD 34 cell dose infused  10^6/kg
Mean 5.9
Range 3.59-10.17416
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Use of UCB as an alternative SC source is limited due to inade-
quate TNC&CD34+ cells, in that it is often difficult to find a single
unit for successful engraftment in adolescents & adults. One strategy
to overcome this limitation is to increase the number of cells by ex-
pansion of HPC. StemExwas developed as a cell graft based on use
of a copper chelator (TEPA) that delays differentiation & promotes
expansion of HPC with engraftment capabilities. StemEx is manu-
factured from a fraction of a single CBU originally frozen in 2 sep-
arate fractions. CD133+ progenitor cells purified from the smaller
or equal fraction are cultured for 21 days with cytokines & TEPA.
The product is transplanted to the patient 24h after infusion of the
unmanipulated fraction. A global pivotal Phase II/III registration
study is underway to evaluate the safety & efficacy of StemEx in
patients with advanced hematological malignancies.
Taking into consideration the variability in the intrinsic potential
& the cryopreservation processes of the CBUs, successful & robust
manufacturing of clinical batches is one of the major challenges of
this study. 61 StemEx batches have been manufactured so far in 3
centralized GMP facilities in US, EU & Israel. All the fresh hand-
carried batches were successfully delivered to the centers within
the StemEx stability period. Of the 61 batches, 58 successfully passed
the in-process & final process quality control (IPQC & FPQC) cri-
teria: median fold expansion of TNC, CD34+ cells & CFU over cul-
ture input values were 377 (52-743, n 5 58), 74 (6-206, n 5 57) &
111 (43-662, n 5 56), respectively. Expansion of only a portion of
the CBU resulted in a median 9.6 fold increase (0.8-90.3 n 5 58)
in the total number of CD34+ cells infused, over the theoretical num-
ber of CD34+ cells that would be infused from the entire CBU with-
out expansion. Interestingly, all three batches that failed to expand
also did not pass the IPQC criteria:$ 10 CFU/1000 freshly purified
CD133+ cells at day 0 of production. This information, available be-
fore initiation of patient myeloablation, provides further confidence
regarding the quality of the CBU & the StemEx product.
With the significant production challenges of an ex vivo expanded
product being successfully met in the current registration trial, Ste-
mEx study demonstrates the feasibility of this approach in satisfying
an urgent unmet clinical need in the UCB transplantation setting.417
A NOVEL SEQUENTIAL TREATMENT UTILIZING CPX-351 AS SALVAGE
CHEMOTHERAPY FOLLOWED BY A REDUCED INTENSITY CONDITIONING
ALLOGENEIC STEM-CELL TRANSPLANTATION FOR PATIENTS WITH
REFRACTORY LEUKEMIA
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Cytoreduction followed by Reduced Intensity Conditioning
(RIC) may lead to improved results in allogeneic stem cell transplant
(SCT) for refractory leukemia. CPX-351 is a novel liposomal formu-
lation that encapsulates the combination of cytarabine and daunoru-
bicin in a fixed 5: 1 ratio. In vitro, it selectively concentrates in the
marrow. Clinically, CPX-351 is well tolerated, with a favorable tox-
icity profile. In a phase I trial, patients with refractory acute leukemia
were treated with escalating doses of CPX-351 starting at 60 mg/m2
on days - 28, -26 and -24 followed by RIC with IV busulfan 3.2 mg/
kg/day on days -6 to -3 and fludarabine 30 mg /m2/day on days -6 to
-3 (Bu/Flu). GVHD prophylaxis with tacrolimus and methotrexate.
The protocol was amended to include a second arm, B to shorten the
duration prior to stem cell infusion to 3 weeks. Fifteen patients
(AML-12, ALL-2, CML in blast crisis-1) have been enrolled to
date. Five patients are inevaluable due to short follow up (2), sepsis
resulting in aborted transplant plans (2) and donor’s unavailability
(1). Ten patients underwent SCT are evaluable (AML-8, ALL-2).
All patients received HLA compatible grafts (MUD-8, MRD-2).
Three patients had primary induction failure and 7 had relapsed re-
fractory disease. All evaluable patients achieved adequate neutrophil
engraftment at a mean of 16.6 days (range 12-35). Nine patients
achieved adequate platelet engraftment at a mean of 15.8 days (range
11-33). Eight patients achieved complete hematologic and cytoge-
netic remission upon full blood counts recovery. One patient had
full neutrophil and platelets engraftment but did not have a bone
marrow biopsy as of this date. Two patients (ALL) had a disease re-
lapse 24 and 60 days post transplant. Acute GVHDoccurred in 3 pa-
tients. One patient with a stage 2 skin GVHD and 2 patients had
stage 3-4 GI GVHD upon cessation of immunosupression 5 and 9
months post transplantation. Grade 3 mucositis developed in 4 pa-
tients.The 100 days overall survival and disease free survival for 8
evaluable patients was 85% and 78% respectively. At a mean follow
